We are very proud to be able to share the results from an early HTA (Health Technology Assessment) on ACS (Acute Coronary Syndrome) showing that the use of HealthB is cost-effective for both a healthcare and societal perspective when used for secondary prevention in Norway!
The study showed that:
✔️ HealthB lowers healthcare costs
✔️ HealthB increases QALYs (quality-adjusted life year) for a healthcare and societal perspective
✔️HealthB increases life years for a healthcare and societal perspective
The analysis also found that, from a healthcare perspective, HealthB can be cost-effective even if the annual subscription costs increase by +/- 300%!
The results are taken from a master's thesis conducted by Prayash Chaudhary as part of the Master of Philosophy Degree in Health Economics, Policy and Management, Faculty of Medicine, University of Oslo, Department of Health Management and Health Economics, under supervision of Torbjørn Wisløff.
Congratulations Prayash for this achievement!!💫 We are immensely grateful for having you with us on this project and for the effort you put into this! Looking forward to celebrate together soon!🥂
📖 Cardiovascular disease (CVD) is the second leading cause of death in Norway. Treatment and aftercare costs of CVD events are very high. Angina and myocardial infarction are the most common types of CVD in Norway. Unstable angina and acute myocardial infarction are commonly termed ACS. Poor medication and cardiac rehabilitation adherence due to a lack of understanding of medication and side effects of medication, treatment plan and mere forgetfulness lead to an increased risk of secondary CVD events among ACS patients. Secondary prevention refers to preventing e.g. heart attack and stroke through drug therapy and counseling of high risk individuals, such as those with previous events or known CVD.
Interested in learning more about these results or read the full master’s thesis? Leave a comment below and we’ll be in touch👇😊